Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	CXCL12	Synonyms	IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1	Type of gene	protein-coding
Chromosome	10	Map location	10q11.21	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	C-X-C motif chemokine ligand 12

GTO ID	GTC2205
Trial ID	NCT04121455
Disease	Glioblastoma
Altered gene	CXCL-12
Therapeutic/Target gene	Target gene
Therapy	Aptamer
Treatment	NOX-A12\|olaptesed pegol
Co-treatment	Radiotherapy
Phase	Phase1\|Phase2
Recruitment status	Active, Not Recruiting
Title	Single-arm Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a 3-arm Expansion Group Including Fully Resected Patients and Combination With Bevacizumab or Pembrolizumab
Year	2019
Country	Germany
Company sponsor	TME Pharma AG
Other ID(s)	SNOXA12C401\|2018-004064-62

Cohort1: NOX-A12_dose level1

Administration route	intravenous infusion
Dosage	NOX-A12, 200 mg, weekly for 26 weeks\|Radiotherapy, umulative dose of 60 Gy in 2 Gy fractions, in weeks 1-6
Age	Adult, Older_Adult
References	PMID: 38806504

Cohort2: NOX-A12_dose level2

Administration route	intravenous infusion
Dosage	NOX-A12, 400 mg, weekly for 26 weeks\|Radiotherapy, umulative dose of 60 Gy in 2 Gy fractions, in weeks 1-6
Age	Adult, Older_Adult
References	PMID: 38806504

Cohort3: NOX-A12_dose level3

Administration route	intravenous infusion
Dosage	NOX-A12, 600 mg, weekly for 26 weeks\|Radiotherapy, umulative dose of 60 Gy in 2 Gy fractions, in weeks 1-6
Age	Adult, Older_Adult
References	PMID: 38806504

Cohort4: NOX-A12_dose level3_Bevacizumab

Administration route	intravenous infusion\|intravenous injection
Dosage	NOX-A12, 600 mg, weekly for 26 weeks\|Radiotherapy, umulative dose of 60 Gy in 2 Gy fractions, in weeks 1-6\|Bevacizumab, 10 mg/kg, every 2 weeks for 26 weeks
Age	Adult, Older_Adult
References	PMID: 38806504

Cohort5: NOX-A12_dose level3_completely resected patients

Administration route	intravenous infusion
Dosage	NOX-A12, 600 mg, weekly for 26 weeks\|Radiotherapy, umulative dose of 60 Gy in 2 Gy fractions, in weeks 1-6
Age	Adult, Older_Adult
References	PMID: 38806504

Cohort6: NOX-A12_dose level3_Pembrolizumab

Administration route	intravenous infusion\|intravenous injection
Dosage	NOX-A12, 600 mg, weekly for 26 weeks\|Radiotherapy, umulative dose of 60 Gy in 2 Gy fractions, in weeks 1-6\|Pembrolizumab, 200 mg, every three weeks for 26 weeks
Age	Adult, Older_Adult
References	PMID: 38806504

Overview of Knowledge Graph